Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04161755 · ClinicalTrials.gov registry record · Phase 1

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

A Phase 1 study of Pancreatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
29
Enrollment target
7
Study locations

NCT04161755: Active Phase 1 study of Pancreatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04161755 is a Phase 1 study of Pancreatic Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04161755, a Phase 1 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
29 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

Primary Outcome

The primary objective of this trial is to evaluate the safety of a personalized tumor vaccine combined with atezolizumab and mFOLFIRINOX

Conditions Studied

Interventions

  • DRUG Atezolizumab
  • DRUG mFOLFIRINOX
  • BIOLOGICAL RO7198457

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2019-12-13
Est. Completion 2026-11-11
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04161755 still lists

NCT04161755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT04161755 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT04161755 about?

NCT04161755 is a clinical study titled "Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery". The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

What is the current status of trial NCT04161755?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-12-13. Estimated completion is 2026-11-11.

What conditions does trial NCT04161755 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT04161755?

The interventions under investigation include: Atezolizumab (DRUG), mFOLFIRINOX (DRUG), RO7198457 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04161755?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04161755 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04161755's enrollment target sits among peer trials

29 197th of 278 higher than 81 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04161755, the US trial registry maintained by the National Library of Medicine. NCT04161755 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.